South Korea Multi Cancer Early Detection Market Size & Outlook
- Clinical Diagnostics
- Cancer Diagnostics
- Multi Cancer Early Detection Market Outlook
- Cancer Diagnostics
Global Market
Related Markets
Ask Prism AI anything about the multi cancer early detection market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
South Korea multi cancer early detection market highlights
- The South Korea multi cancer early detection market generated a revenue of USD 35.3 million in 2024 and is expected to reach USD 99.2 million by 2030.
- The South Korea market is expected to grow at a CAGR of 18.8% from 2025 to 2030.
- In terms of segment, gene panel, ldt & others was the largest revenue generating type in 2024.
- Liquid Biopsy is the most lucrative type segment registering the fastest growth during the forecast period.
Multi cancer early detection market data book summary
| Market revenue in 2024 | USD 35.3 million |
| Market revenue in 2030 | USD 99.2 million |
| Growth rate | 18.8% (CAGR from 2025 to 2030) |
| Largest segment | Gene panel, ldt & others |
| Fastest growing segment | Liquid Biopsy |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Liquid Biopsy, Gene Panel, LDT & Others |
| Key market players worldwide | Illumina Inc, Exact Sciences Corp, Foundation Medicine, Guardant Health Inc, Burning Rock Biotech Ltd ADR, Freenome, AnchorDx, GeneCast, Elypta |
Other key industry trends
- In terms of revenue, South Korea accounted for 3.2% of the global multi cancer early detection market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China multi cancer early detection market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 160.3 million by 2030.
Increasing R&D investments by key pharmaceutical companies in South Korea are expected to create a lucrative environment for market growth. For instance, in October 2022, AstraZeneca announced that it will spend USD 630.0 million on R&D in South Korea over the next 5 years to improve access to healthcare.
No credit card required*
Publish Date: Feb 19, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Multi Cancer Early Detection Market Scope
Multi Cancer Early Detection Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Guardant Health Inc | View profile | 1,779 | 3100 Hanover Street, Palo Alto, CA, United States, 94304 | www.guardanthealth.com |
| Exact Sciences Corp | View profile | 6,600 | 5505 Endeavor Lane, Madison, WI, United States, 53719 | www.exactsciences.com |
| Freenome | View profile | 501-1000 | South San Francisco, California, United States, North America | www.freenome.com |
| Foundation Medicine | View profile | 251-500 | Cambridge, Massachusetts, United States, North America | www.foundationmedicine.com |
| Burning Rock Biotech Ltd ADR | View profile | 786 | No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, China, People's Republic of, 510005 | www.brbiotech.com |
| AnchorDx | View profile | 51-100 | Guangzhou, Guangdong, China, Asia | www.anchordx.com/ |
| GeneCast | View profile | 1-10 | Seoul, Seoul-t'ukpyolsi, South Korea, Asia | genecast.co.kr |
| Elypta | View profile | 11-50 | Stockholm, Stockholms Lan, Sweden, Europe | www.elypta.com/ |
South Korea Multi Cancer Early Detection Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Multi Cancer Early Detection Market Outlook will help companies and investors design strategic landscapes.
Gene Panel, Ldt & Others was the largest segment with a revenue share of 107.93% in 2024.
Horizon Databook has segmented the South Korea multi cancer early detection market based on liquid biopsy, gene panel, ldt & others covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing R&D investments by key pharmaceutical companies in South Korea are expected to create a lucrative environment for market growth. For instance, in October 2022, AstraZeneca announced that it will spend USD 630.0 million on R&D in South Korea over the next 5 years to improve access to healthcare.
- South Korea Multi Cancer Early Detection Market Type Outlook (Revenue, USD Million , 2018-2030)
- Liquid Biopsy
- Gene Panel, LDT & Others
- South Korea Multi Cancer Early Detection Market End Use Outlook (Revenue, USD Million , 2018-2030)
- Hospitals
- Diagnostic Laboratories
- Others
Reasons to subscribe to Multi Cancer Early Detection Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Multi Cancer Early Detection Market Outlook databook
- Our clientele includes a mix of Multi Cancer Early Detection Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea Multi Cancer Early Detection Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Korea Multi Cancer Early Detection Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
South Korea Multi Cancer Early Detection Market, 2018-2030 (US$M)
South Korea multi cancer early detection market statistics, by type, 2018-2030 (US$M)
